Release Date: July 31, 2024
Expiration Date: July 31, 2025

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Acute myeloid leukemia (AML) is a challenging, complex disease to treat; while intensive chemotherapy is a standard of care for patients who are medically fit, patients who are older or frail are often not eligible for intensive chemotherapeutic regimens and have both poorer prognoses and reduced survival times. These patients also often have complex disease subtypes, including IDH1, FLT3 and TP53, which further complicate treatment decisions. In this accredited activity, a panel of national and international experts discuss standards care for both fit and unfit patients with AML, the role of genetic testing in both diagnosis and treatment, and strategies for tailoring therapeutic regimens to individual disease subtypes in patients who are unfit for intensive chemotherapy.

Target Audience

The target audience for these activities includes hematologists/oncologists and other healthcare providers involved in the treatment of patients with AML.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Outline current standards of care for intensive chemotherapy in patients with AML
• Summarize current complexities and limitations in the current management of patients with AML who are unfit for intensive chemotherapy
• Identify disease and clinical factors specific for AML that render patients unsuitable for intensive chemotherapy
• Evaluate current approaches to the treatment of older, fit patients with AML and the evolving use of non-intensive therapies in this patient subgroup

Agenda

Instructions for Participation and Credit

This activity is eligible for credit through July 31, 2025. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME, CE, and CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Eytan M. Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Eytan Stein is the Chief of the Leukemia Service, Associate Attending Physician, Clinical Investigator, and Director of the Program for Drug Development in Leukemia on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He conducts novel, phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies. Dr. Stein led the clinical studies of the IDH2 inhibitor enasidenib and the IDH1 Inhibitor ivosidenib in patients with relapsed and refractory AML that led to their FDA approval in 2017 and 2018, respectively. He also leads a variety of phase 1 clinical trials and serves as the lead investigator at Memorial Sloan Kettering for the BEAT AML master clinical trial.

His current research focuses on elucidating mechanisms of resistance to IDH inhibitors and the use of Menin inhibitors in patients with MLL-rearranged acute leukemia. His work has been published in journals such as Nature, Nature Medicine, The New England Journal of Medicine, JAMA Oncology, Cancer Discovery and Blood. In addition, he serves on the editorial boards of Blood and Leukemia and Lymphoma.

David Sallman, MD
Leukemia & MDS Section Head
Associate Member
Department of Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Assistant Professor, Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Dr. David Sallman is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center and Assistant Professor in the Department of Oncologic Sciences at the University of South Florida (USF), both in Tampa. Dr. Sallman is the Myeloid Section Head of the Malignant Hematology Department. He earned his medical degree from the USF College of Medicine and completed an internal medicine residency at Massachusetts General Hospital before completing a Hematology/Oncology Fellowship at Moffitt. He is board certified in medical oncology, hematology, and internal medicine.

His clinical interests are in MDS, AML, and myeloproliferative neoplasms. His research interests focus on the development of novel targeted therapeutic strategies for patients with MDS and AML. Dr. Sallman has published in leading journals such as Leukemia, Blood, and Journal of Clinical Oncology. He is the PI for multiple ongoing studies focused on higher-risk MDS and has authored or coauthored numerous articles, books, book chapters, and abstracts; and serves as reviewer for multiple journals.

Marion Subklewe, MD
Head of the Laboratory for Translational Cancer Immunotherapy
Professor of Internal Medicine
Ludwig Maximilian University
Munich, Germany

Dr. Marion Subklewe is Professor of Internal Medicine with a focus on Cellular Immunotherapy within the medical department for Hematology/Oncology at the Ludwig Maximilian University (LMU) – University Hospital Munich. She is Head of the Immunotherapy Program in Hematology and the CAR T program at the University Hospital Munich, leading an intermediate care unit and an early clinical trial unit as well as a large outpatient clinic for patients with acute leukemias and aggressive lymphomas. She is heading the lab for Translational Cancer Immunotherapy at the Gene Center Munich with a focus on translational research in T-cell based immunotherapy.

Her research is focused on understanding the mode of action and the mode of resistance of bispecific and bifunctional antibody constructs. Current research integrates an adapter CAR T-cell platform and combinatorial approaches in the setting of AML. She is a speaker for the national “Harmonize MRD Flow” consortium and a member of the ELN working group on MRD. She is Principal Investigator in I-IT trials in AML and ALL as well as in > 30 oligo – and multicentric C-IT trials in leukemias and lymphoma.

Accreditation

	CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	NURSING CREDIT MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 24-026-182

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures

Dr. Eytan Stein has relevant financial relationships related to formal advisory activities from and owns significant holdings in Abbvie, Inc., Agios, Inc., Astellas Pharma US, Inc., Auron Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation – a Bristol-Myers Squibb Company, Genentech, Inc., Gilead, Janssen Pharmaceuticals, Inc., Syndax Pharmaceuticals and Syros Pharmaceuticals, Inc.

Dr. David Sallman has relevant financial relationships related to formal advisory/consultant activities from Abbvie, Inc., Affimed GmbH, Astellas Pharma US, Inc., AvenCell Therapeutics, Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, Dark Blue Therapeutics, Foghorn Therapeutics, Gilead, Incyte Corporation, Intellia Therapeutics, Inc., Intellisphere LLC, Jasper Therapeutics, Inc., Kite Pharma, Inc. – a Gilead Company, Magenta Therapeutics, Molecular Partners AG, Nkarta, Inc., PGEN Therapeutics, Inc., Orbital Therapeutics Inc., Rigel Pharmaceuticals, Inc., Shattucks Labs, Inc., Servier, Syndax Pharmaceuticals, Syros Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited and Zentalis Pharmaceuticals, Inc.; and has received research support from Aprea Therapeutics and Jazz Pharmaceuticals, Inc.

Dr. Marion Subklewe has no relevant financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices. 

Planning Committee

Joan Meyer, RN, MHA, Executive Director; Sheri Sturgis, Strategy and Education Manager; Lillian McVey, Content Director; and Jennifer Murphy, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Pfizer, Inc.

©2024 MediCom Worldwide, Inc., 4607 Library Rd., Ste. 220 #2001 · Bethel Park, PA 15102, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.